Anthrax: Single dose intranasal vaccine, NasoShield, Phase 1b clinical trial
by Press Release from Outbreak News Today on (#557EB)
Altimmune, Inc. announced today dosing of the first patient in the Company's Phase 1b clinical trial of NasoShield, a single dose intranasal anthrax vaccine candidate. NasoShield is the only single dose anthrax vaccine in development that is supported by BARDA, and has the potential to provide a significant improvement over the available two- and three-dose [...]
The post Anthrax: Single dose intranasal vaccine, NasoShield, Phase 1b clinical trial appeared first on Outbreak News Today.